Skip to main content
. Author manuscript; available in PMC: 2012 May 29.
Published in final edited form as: Endocr Relat Cancer. 2011 Jul 1;18(4):413–428. doi: 10.1530/ERC-11-0075

Figure 4. Involvement of EGFR transactivation in Notch1 and survivin induction in the presence of leptin.

Figure 4

A) Breast cancer cells were untreated (U) or treated with leptin (L). Lysates were immunoprecipitated with EGFR antibody and probed with anti-Phospho-tyrosine antibody. The membranes were re-blotted using anti-EGFR antibody as control. Leptin induces phosphorylation of EGFR. B) Breast cancer cells were transfected with EGFR-siRNA and treated with or without leptin (L). EGFR-siRNA resulted in EGFR silencing. Leptin treatment does not induce Notch1 expression when EGFR is silenced. C) Breast cancer cells were pretreated with EGFR inhibitor followed by leptin treatment as indicated (In.+L). Cells were also treated with leptin alone (L) or inhibitor alone (In.). Untreated cells are denoted with U. Lysates were probed with indicated antibodies. EGFR inhibition by erlotinib inhibits leptin-induced survivin expression.